HomeAI · summaries
Storia in 17 fonti
ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer - Pharmaceutical Technology
The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
pbs.org
Pancreatic cancer is deadly and difficult to treat. A new pill could change that
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
- ·
biopharmadive.com
‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer
Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.
